NFL Biosciences SA ALNFL
EURONEXT · France · Health Technology
€0.65000.00 (0.00%)
Market open· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Dublin, Sept. 10, 2026 (GLOBE NEWSWIRE) -- The "NFL-101 Sales Forecast, and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering. The report provides a comprehensive assessment of NFL-101 for smoking cessation across the seven major pharmaceutical markets: the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan. The report evaluates the therapy's clinical development, commercial potential, competitive positioning, regulatory milestones, pricing
MONTPELLIER, France, September 08, 2026--Regulatory News: NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing innovative botanical drugs for the treatment of addictions, announces today that the scientific communication entitled "Baseline IgG1 Levels as a Candidate Predictive Biomarker of NFL-101 Efficacy in Smoking Cessation: A Post-hoc Analysis of the CESTO2 Phase II Randomized Controlled Trial" has been selected for an oral presentation by th
MONTPELLIER, France, July 28, 2026--Regulatory News: NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing innovative botanical drugs for the treatment of addictions, today announced that it has submitted an application to the French National Agency for Medicines and Health Products Safety (ANSM) and the Committee for the Protection of Human Subjects (CPP) for authorization of its TONIC clinical trial, the first study to evaluate NFL-102 in smoker
MONTPELLIER, France, July 07, 2026--Regulatory News: NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing innovative botanical drugs for the treatment of addictions, announces today that three scientific communications dedicated to its drug candidates NFL-101 and NFL-102 have been accepted for presentation at the 2026 Annual SRNT-Europe Conference, which will be held in Paris from 21 to 23 September 2026. SRNT-Europe is the European chapter of th
MONTPELLIER, France, June 30, 2026--Regulatory News: NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing innovative botanical drugs for the treatment of addictions, announces today the successful manufacturing of a GMP (Good Manufacturing Practice) clinical batch of NFL-102, a new drug candidate for smoking cessation.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.